Johnson & Johnson projects at least 3% growth in operating sales for the year 2025.
The U.S. company expects to achieve an increase in operating sales between 5% and 6% next year, excluding sales of Covid vaccines, which represents a slowdown compared to the 8.5% to 9% estimate for 2023.
In the long term, the company anticipates sustained growth of at least 3% in operating sales for 2025, despite the entry of a 'Stelara' biosimilar into the U.S. market.
The compound annual growth rate (CAGR) is estimated between 5% and 7% from 2025 to 2030.
Regarding adjusted operating earnings per share, it is expected to range between $10.55 and $10.75, with 7.3% growth at the midpoint of the range.
This includes an impact of approximately $0.15 per share related to the acquisition of Laminar.
Joaquín Duato, president and chief executive officer of J&J, has stated that science and technology will drive the advancement of human health in the coming decade, leading to more effective and personalized treatments, earlier interventions, and smarter and less invasive healthcare.
Duato also highlighted Johnson & Johnson's unique position to lead the next wave of innovation and provide solid financial performance thanks to its scientific capabilities, diverse portfolio, and strong projects.
With information from: Diario de Sevilla.
Receive all industry news in our weekly Scientific Dialectics Newsletter.